| Outcome Measures: |
Primary: HbA1c, Change in glycated hemoglobin (HbA1c) values relative to baseline after 26 weeks of treatment, Baseline, Week 26 | Secondary: The proportion of HbA1c <6.5% and <7%, Proportion of subjects with HbA1c \<7% and HbA1c \<6.5% after 26 and 54 weeks of treatment, Baseline, Week 26,Week 54|HbA1c, Change in HbA1c relative to baseline after 6, 10, 14, 20, 38, and 54 weeks of treatment., Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54|fasting plasma glucose (FPG), Change in fasting plasma glucose (FPG) relative to baseline after 6, 10, 14, 20, 38, and 54 weeks of treatment., Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54|fasting insulin, Change in fasting insulin relative to baseline after 14, 26, and 54 weeks of treatment., Baseline, Week 14,Week 26,Week 54|Homeostatic Model Assessment of Insulin Resistance(HOMA-IR), Change in HOMA-IR relative to baseline after 26 and 54 weeks of treatment., Baseline,Week 26,Week 54|Health Survey Short Form (SF-36), Value of change in Health Survey Short Form (SF-36) scores relative to baseline after 26 and 54 weeks of treatment., Baseline,Week 26,Week 54|blood pressure, Change in blood pressure (sitting) relative to baseline after 26 and 54 weeks of treatment. The blood pressure includes systolic and diastolic blood pressure., Baseline,Week 26,Week 54
|
